ASCOT's trial proves Amlodipine-based regimen reduced diabetes risk by 34 % in BP patients
Thursday, October 12, 2006 16:00 IST Our, Bangalore
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the world's largest study of hypertensive patients has proved that Amlodipine-based regimen reduces risk of new-onset diabetes by 34 per cent in hypertensive patients.
